Rezolute Management
Management criteria checks 3/4
Rezolute's CEO is Nevan Elam, appointed in Jan 2013, has a tenure of 11.92 years. total yearly compensation is $1.19M, comprised of 46.1% salary and 53.9% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $36.27K. The average tenure of the management team and the board of directors is 2.9 years and 4.3 years respectively.
Key information
Nevan Elam
Chief executive officer
US$1.2m
Total compensation
CEO salary percentage | 46.1% |
CEO tenure | 11.9yrs |
CEO ownership | 0.01% |
Management average tenure | 2.9yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
May 22Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Feb 13Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 21Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation
Jul 25We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth
Jan 31Rezolute GAAP EPS of -$0.37
Sep 15We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
May 06Rezolute shares rise on positive topline results from RZ402 eye disease trial
May 04What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?
Jan 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$69m |
Jun 30 2024 | US$1m | US$550k | -US$68m |
Mar 31 2024 | n/a | n/a | -US$58m |
Dec 31 2023 | n/a | n/a | -US$57m |
Sep 30 2023 | n/a | n/a | -US$56m |
Jun 30 2023 | US$974k | US$534k | -US$52m |
Mar 31 2023 | n/a | n/a | -US$48m |
Dec 31 2022 | n/a | n/a | -US$44m |
Sep 30 2022 | n/a | n/a | -US$43m |
Jun 30 2022 | US$8m | US$515k | -US$41m |
Mar 31 2022 | n/a | n/a | -US$38m |
Dec 31 2021 | n/a | n/a | -US$31m |
Sep 30 2021 | n/a | n/a | -US$25m |
Jun 30 2021 | US$5m | US$496k | -US$21m |
Mar 31 2021 | n/a | n/a | -US$18m |
Dec 31 2020 | n/a | n/a | -US$19m |
Sep 30 2020 | n/a | n/a | -US$19m |
Jun 30 2020 | US$4m | US$490k | -US$20m |
Mar 31 2020 | n/a | n/a | -US$20m |
Dec 31 2019 | n/a | n/a | -US$37m |
Sep 30 2019 | n/a | n/a | -US$34m |
Jun 30 2019 | US$732k | US$453k | -US$33m |
Mar 31 2019 | n/a | n/a | -US$42m |
Dec 31 2018 | n/a | n/a | -US$25m |
Sep 30 2018 | n/a | n/a | -US$27m |
Jun 30 2018 | US$468k | US$450k | -US$30m |
Compensation vs Market: Nevan's total compensation ($USD1.19M) is about average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Nevan's compensation has increased whilst the company is unprofitable.
CEO
Nevan Elam (57 yo)
11.9yrs
Tenure
US$1,192,700
Compensation
Mr. Nevan Charles Elam, J.D., is a Founder of Rezolute, Inc. and serves as its Chief Executive Officer and Director at since January 31, 2013. Mr. Elam serves as Acting Chairman of the Board at Rezolute, I...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 11.9yrs | US$1.19m | 0.013% $ 36.3k | |
Chief Financial Officer | less than a year | US$384.07k | 0.30% $ 806.9k | |
Chief Medical Officer | 4.9yrs | US$817.96k | 0.12% $ 318.9k | |
Director and Head of Scientific & Patient Affairs | 3.6yrs | no data | no data | |
Senior VP & Head of Corporate Development | 1.9yrs | no data | no data | |
Senior VP & Head of Program & Portfolio Management | 3.8yrs | no data | no data | |
VP & Head of Finance | no data | no data | no data | |
VP & Head of Ophthalmological Clinical Development | no data | no data | no data | |
VP & Head of Quality | no data | no data | no data | |
Senior VP & Head of Clinical Operations | no data | no data | no data | |
Chief Regulatory Officer | 2.2yrs | no data | no data | |
Senior Vice President of Global Clinical Development | less than a year | no data | no data |
2.9yrs
Average Tenure
53.5yo
Average Age
Experienced Management: RZLT's management team is considered experienced (2.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 11.9yrs | US$1.19m | 0.013% $ 36.3k | |
Member of the Scientific Advisory Board | 10.7yrs | no data | no data | |
Independent Director | 5.1yrs | US$93.44k | 0.098% $ 262.5k | |
Independent Director | 4.3yrs | US$90.44k | 0% $ 0 | |
Director | 5.8yrs | US$45.00k | 0.20% $ 535.7k | |
Board Observer | no data | no data | no data | |
Member of the Scientific Advisory Board | 3.6yrs | no data | no data | |
Independent Director | 3.8yrs | US$86.44k | 0% $ 0 | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.8yrs | US$93.44k | 0.072% $ 193.8k | |
Member of the Scientific Advisory Board | 3.3yrs | no data | no data | |
Board Observer | no data | no data | no data |
4.3yrs
Average Tenure
57yo
Average Age
Experienced Board: RZLT's board of directors are considered experienced (4.3 years average tenure).